Actively Recruiting
A Randomized Study of Intravenous Obrixtamig Combined With Carboplatin and Etoposide Versus Standard Chemotherapy Alone for Adults With DLL3-positive Advanced Extrapulmonary Neuroendocrine Cancer
Led by Boehringer Ingelheim · Updated on 2026-10-28
390
Participants Needed
168
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of adding obrixtamig, an antibody-like medicine, to standard chemotherapy carboplatin and etoposide for adults with advanced extrapulmonary neuroendocrine cancer. The study aims to see if this combination improves survival compared to chemotherapy alone. The study also tests a new medical device to measure levels of a tumor marker called delta-like ligand 3 DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus standard chemotherapy infusions, followed by obrixtamig alone for up to three years. The other group receives standard chemotherapy infusions only for about four months. Treatments are given through a vein. Participants in the obrixtamig group stay overnight at the study site after the first two treatments. During the study, all participants visit the study site regularly for health checks and monitoring for side effects. Doctors measure tumor size at some visits and compare results between the two groups to evaluate treatment effects. The main measure is overall survival up to 38 months. Other assessments include progression-free survival, physical functioning, response duration, and treatment side effects. The study continues until December 2029.
CONDITIONS
Brief Title
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here